key: cord-0036973-l36rzqnx authors: Park, Hyun-Ju; Park, So-Jung title: Virtual Screening for RNA-Interacting Small Molecules date: 2012-08-24 journal: Biophysical approaches to translational control of gene expression DOI: 10.1007/978-1-4614-3991-2_12 sha: 520e7c315b1b235460cf34559852e600b336ea68 doc_id: 36973 cord_uid: l36rzqnx Computational virtual screening is useful and powerful strategy for rapid discovery of small biologically active molecules in the early stage of drug discovery. The discovery of a broad range of important biological processes involved by RNA has increased the importance of RNA as a new drug target. To apply structure-based virtual screening methods to the discovery of RNA-binding ligands, many RNA 3D structure prediction programs and optimized docking algorithms have been developed. In this chapter, a number of successful cases of virtual screening targeting RNA will be introduced. The docking process concerns the prediction of ligand conformation and orientation within a targeted binding site (active site) (Kitchen et al. 2004 ) . In order to carry out docking calculations, it is necessary to know the 3-dimensional (3D) structure of a target and the nature of the binding site. 3D structures are identi fi ed by X-ray crystallography or NMR experiments and can be downloaded from Protein Data Bank (PDB) (Berman et al. 2000 ) or predicted by homology modeling using various programs. The next step is to de fi ne the binding site by known information or prediction. When input is prepared, chemical compounds present in the database are docked into the de fi ned binding site of the selected target receptor. There are two purposes of docking studies. One is to predict accurate ligand binding orientation referred as "molecular modeling" and the other is to predict activity or binding af fi nity referred as "scoring." A docking result is evaluated by ligand binding orientation through visual inspection and by binding af fi nity using the scoring function. Scoring function is designed to predict the biological activity or binding af fi nity through the evaluation of interactions between ligands and receptor (Halperin et al. 2002 ) . Among various docking programs (Table 12 .1 ), the most widely used programs are AutoDock (Morris et al. 1998 ; Huey et al. 2007 ) , DOCK (Ewing et al. 2001 ) , FlexX (Kramer et al. 1999 ; Stahl 2000 ) , Gold (Jones et al. 1995 ) , Glide (Zhou et al. 2001 ) , Internal Coordinate Mechanics (ICM) (Abagyan and Totrov 1994 ) , and Sur fl ex-Dock (Jain 2003 ; Kellenberger et al. 2004 ) . AutoDock is an automated fl exible docking program designed to predict how small molecules (ligands) bind into the receptor structure. AutoDock is performed with an empirical free energy force fi eld based on a Lamarckian genetic algorithm, to bring about speedy prediction of conformation with calculated free energies of association (Morris et al. 1998 ) . This program has application in X-ray crystallography, structure-based drug design, virtual screening, and protein-protein interaction studies. DOCK was introduced by the Kuntz group at UCSF and uses a rigid body docking algorithm and fl exible ligand docking algorithm to dock the ligand into a negative image of the binding pocket (Ewing et al. 2001 ) . FlexX is a fully automatic computer program for predicting protein-ligand interaction. FlexX can predict not only the lowest energy geometry of the complex of ligand with protein but also the binding af fi nities using an empirical scoring function (Böhm 1994 ) . The descriptions of other widely used docking programs including commercial and free softwares are listed in Table 12 .1 . In recent years, while the number of identi fi ed RNA sequences has rapidly increased, the number of known 3D structures has not kept pace with it. For this reason, there is a large gap between the number of known RNA sequences and 3D structures. For example, tRNA is one of the most structurally well characterized RNAs and its 1,101,833 characterized sequences are reported in the Rfam (Gardner et al. 2009 Many clinical antibiotics including macrolides, aminoglycosides, and others targeting bacterial ribosomal RNA (rRNA) reveal that RNA is the important target for drug development (Knowles et al. 2002 ; Hermann 2005 ) . The appearance of drug resistance is the most critical problem in treating bacterial (Neu 1992 ) and viral infections (Perrin and Telenti 1998 ) . RNAs contain highly conserved structural and functional motifs that may serve as drug targets, so the development of resistance to drugs targeting RNA can be slower than that to drugs targeting protein (Gallego and Varani 2001 ) . In contrast to DNA, which mostly has a double-stranded helix structure, RNA is generally single-stranded and folds into complex 3D structures that provide unique pockets for small molecules (Foloppe et al. 2006 ) , thus making RNA an attractive drug target. In spite of these advantages, RNA has not been focus of structure-based drug design, not only due to lack of information of RNA 3D structures, but also due to the sequence-speci fi c unique features of the binding pockets in RNA. The binding pocket of protein usually lies deep in an internal region, separated from solvent. In RNA targets, the binding pockets are large and fl at, located along the surface, and relatively exposed to solvent. Therefore, in using docking algorithms to discover RNAbinding drugs, the physicochemical properties of RNA, such as conformational fl exibility, high negative charge, and solvation, should be taken into account more accurately than those for proteins. Despite such differences between protein and RNA targets, classical protein-ligand docking programs have sometimes successfully performed in RNA-targeted virtual screenings. For example, Kuntz fi rst reported a successful virtual screening using DOCK 3.5 program to identify small molecules in the Available Chemicals Directory (ACD) that targeted an RNA double helix (Chen et al. 1997 ) . Following the fi rst study, many research groups have reported successful studies of virtual screening targeting RNA through protein-based docking methods (Filikov et al. 2000 ; Lind et al. 2002 ; Kang et al. 2004 ; Park et al. 2008 Park et al. , 2011 . Meanwhile, since most of the available docking methods were developed for protein targets, their compliance with RNA targets has been evaluated extensively, and recently Li et al. demonstrated that two widely-used protein docking programs, GOLD 4.0 and Glide 5.0, are appropriate for structure-based drug design and virtual screening for RNA targets (Detering and Varani 2004 ; Li et al. 2010 ) . Several modi fi ed algorithms were established for RNA-targeted virtual screening. For example, Morley and Afshar established an empirical scoring function that appropriately describes steric, polar, and charged interactions in RNA-ligand complexes (Morley and Afshar 2004 ) . This scoring function was implanted in RiboDock program and validated for docking screening of a large-size chemical database. Virtual screening with this program successfully identi fi ed novel ligands for the bacterial ribosomal A-site (Foloppe et al. 2004 ) . Moitessier et al. applied a unique method to the AutoDock docking process, taking into account inherent RNA fl exibility and key water molecules, and this modi fi ed docking tool was validated by (Moitessier et al. 2006 ). In Kuntz et al.'s study, 70 experimental RNA-ligand complexes from PDB were re-docked using the DOCK 6 program, and the resulting docked conformations were rescored with AMBER generalized Born/solvent-accessible surface area (GB/SA) and Poisson-Blotzmann/SA (PB/SA) scoring functions in combination with explicit water molecules and sodium counterions. The success rate for reproducing experimental binding modes was signi fi cantly improved by using AMBER GB/SA or PB/SA (Lang et al. 2009 ) . As small molecules induce RNA conformational changes by binding to structures from preexisting dynamic ensembles (Puglisi et al. 1992 ; Zhang et al. 2007 ; Frank et al. 2009 ; Cruz and Westhof 2009 ; Fulle and Gohlke 2010 ) , large conformational changes in RNA receptors after binding with small molecules during virtual screening must be accounted for. However, current protocols do not consider this point, limiting the range of target structures for the discovery of small molecules. Guilbert and James therefore developed a fl exible docking program called MORDOR, which supports fl exibility in the ligand and limited fl exibility in the RNA for induced-fi t binding. MORDOR performed well not only on 57 test sets of RNA-ligand complexes by retrieving experimental poses within 2.5 Å with a 74% success rate, but also in discovering ligands for novel targets such as human telomerase RNA Pinto et al. 2008 ) . When comparing the practicality of DOCK 6 and MORDOR, DOCK 6 screened about 3-10 times faster than MORDOR, while MORDOR performed better on ligands with a large number of rotatable bonds (Lang et al. 2009 ) . Most recently, Al-Hashimi's group reported a new strategy for virtual screening targeting an RNA dynamic ensemble constructed by combining NMR spectroscopy and computational molecular dynamics (MD) (Stelzer et al. 2011 ) . This strategy takes into account large degrees of RNA conformational adaptation during virtual screening. This approach was applied to a search for small molecules for HIV-1 TAR (transactivation response element) RNA ( vide infra ). As one of the best characterized RNA-based regulatory machineries, the interaction of TAR with Tat protein has been focused upon as a target to inhibit HIV-1 replication (Yang 2005 ) . Ligands that inhibit the TAR-Tat interaction can be developed as anti-AIDS drugs. Various molecules for TAR RNA that inhibit Tat binding have been identi fi ed, and many of those molecules were discovered by virtual screening of chemical libraries. In earlier studies, James used automatic docking methods (DOCK and ICM), employing fl exible docking with Monte Carlo simulation and optimized scoring function, identifying phenothiazine compounds from ACD as TAR RNA ligands (Filikov et al. 2000 ; Lind et al. 2002 ) . To circumvent the limitation of incorporating RNA fl exibility for structure-based virtual screening, and to fi nd novel scaffolds for TAR-Tat inhibitors, ligand-based virtual screening was conducted. The SQUID fuzzy pharmacophore search method successfully identi fi ed a novel heterocyclic compound with an order of magnitude improved activity compared to known phenothiazine compounds (Renner et al. 2005 ) . In 2011, Al-Hashimi's group developed the most outstanding technology for RNA-targeted virtual screening through intensive generation of an ensemble of TAR RNA conformers and a robust re-docking validation test. Their strategy was effectively applied to virtual screening of a relatively small-sized chemical library containing 51,000 compounds, and they identi fi ed netilmicin, a selective HIV-1 TAR RNA binder, that inhibited HIV-1 replication in vivo (Stelzer et al. 2011 ) . Details of their study are described below. To test the accuracy of docking, a total of 96 small molecule-bound RNA structures downloaded from the PDB were assessed for docking performance. All docking performances were carried out using the ICM docking program (Abagyan and Totrov 1994 ) and results were evaluated by ICM Score and RMSD between native ligand (extracted from RNA structures) and predicted orientation after docking. The binding energies based on the ICM Score were predicted with high accuracy ( R = 0.71). In more than half of cases (53%), the predicted conformations matched the X-ray or NMR structures within 2.5 Å RMSD. To decide on a suitable RNA ensemble, the accuracies of docking with two sets of RNA ensembles of HIV-1 TAR were compared. One ensemble, named TAR NMR-MD , consisted of 20 conformers generated by SAS selection (select-and-sample strategy, Frank et al. 2009 ) . To construct TAR NMR-MD , HIV-1 TAR structure (PDB id: 1ANR, Aboul-ela et al. 1996 ) was downloaded and molecular dynamics simulations were performed by measuring NMR residual dipolar couplings (RDC) in elongated RNA. The other RNA ensemble, named TAR MD , consisted of 20 randomly selected snapshots from an 80-ns MD simulation of apo-TAR with backbone RMSDs ranging from 3 to 80 Å. The X-ray structure (PDB id: 397D, Ippolito and Steitz 1998 ) and 20 NMR structures (PDB id: 1ANR, Aboul-ela et al. 1996 ) of apo-TAR were downloaded from the PDB. A test set ligand library containing 38 known ligands for TAR RNA was obtained from the published literatures. To test the accuracy of the RNA ensemble, virtual screening of the test set ligands targeting the RNA ensembles, TAR NMR-MD and TAR MD , was conducted, respectively. Virtual screening was conducted using ICM after binding pockets were predicted by the ICM PocketFinder module based on the calculated surface area and volume of cavities on the receptor surface. The results suggested that TAR NMR-MD improved the accuracy of docking compared with TAR MD . From this result TAR NMR-MD was chosen for further virtual screening to identify small molecule TAR-Tat inhibitors. A chemical database consisting of 49,166 compounds was obtained from the Center for Chemical Genomics at the University of Michigan and 2,060 compounds from the author's in-house library. Based on the ICM Score, the top 57 commercially available hit compounds were selected and their binding activities were tested by fl uorescence-based assays. This identi fi ed six small molecules that bound to TAR with high af fi nity ( K d = 55 nM to 122 m M) and inhibited TAR interaction with Tat Ribosomal −1 frameshifting (−1 FS) is an essential event during translation for the synthesis of two or more proteins encoded by overlapping reading frames on a single mRNA (Dinman and Berry 2007 ) in many RNA viruses such as retroviruses, coronaviruses, yeast, plant virus, and even bacteria (Jacks and Varmus 1985 ; Brierley et al. 1991 ; Chamorro et al. 1992 ; Tzeng et al. 1992 ; ten Dam et al. 1994 ; Kang and Tinoco 1997 ; Jacobs et al. 2007 ) . Two cis -acting elements are required to regulate −1 FS. One is a slippery sequence where ribosome-associated tRNAs slip, and the other is RNA secondary structure such as a hairpin or pseudoknot that promotes ribosome pausing. Thermodynamic or kinetic control of RNA secondary structure folding may be important in regulating the ef fi ciency of −1 FS. Human immunode fi ciency virus type 1 (HIV-1) utilizes −1 FS to regulate the expression ratio of Gag to Gag-Pol, which is critical for the production of infectious virion particles (Paulus et al. 1999 ) . The RNA stem-loop sequence that is involved in −1 FS of HIV-1 is highly conserved in the main subtypes of HIV-1 (Gareiss and Miller 2009 ). Mutations of this sequence reduce −1 FS and decrease viral infectivity and replication (Baril et al. 2003 ; Dulude et al. 2006 ) . In severe acute respiratory syndrome coronavirus (SARS-CoV), replicase genes mainly encode two large replicative polyproteins (pp1a and pp1ab) which are expressed by two partially overlapped open reading frames ORF 1a and ORF 1b. As ORF 1b has no independent translation initiation site, polyprotein pp1ab encoded by ORF 1b is only translated as a fused protein form with ORF 1a through −1 FS. As pp1ab includes RNA-dependent RNA polymerase (RdRp) and other replication components which are important proteins for viral replication, −1 FS is essential for the synthesis of enzymatic proteins. The stability of the RNA pseudoknot that induces −1 FS in the SARS-CoV (SARS-pseudoknot) also has a dramatic effect on −1 FS ef fi ciency. Therefore, the RNA secondary structure in the −1 FS site has emerged as an attractive target for drug development (Baranov et al 2005 ; Plant et al 2005 ; Su et al. 2005 ) . Park fi rst conducted virtual screening against the RNA pseudoknot in the −1 FS site to discover ligands that change −1 FS ef fi ciency (Park et al. 2008 ) . In this pilot study, they used the −1 FS system containing biotin aptamer RNA pseudoknot as the RNA secondary structure element. Biotin RNA aptamer was the only ligandbound RNA pseudoknot structure (PDB id: 1F27) determined by X-crystallography (Nix et al. 2000 ) . Park et al. used the conventional 2D and 3D pharmacophore search program Unity (Martin 1992 ) for primary database fi ltering and the FlexX docking program for fi nal docking screening. RNA fl exibility was not considered and ligand fl exibility was given during FlexX run. Out of about 80,000 compounds in the chemical DB, they obtained 37 hits which increased −1 FS. Compound h4 showed the highest activity in the in vitro transcription and translation coupled assay ( Fig. 12.1 ) . The FlexX-docked pose of h4 is shown in Fig. 12.2 . The docking mode of h4 is similar to that of biotin; however, h4 forms a stronger interaction with the receptor RNA (Fig. 12.2a ) . Compound h4 forms hydrogen bonds with O4 ¢ and the 2-carbonyl oxygen of uracil ring of U7 which is one of the critical residues for interaction with biotin in the X-ray structure, and an additional hydrogen bond with ribose O2 ¢ atom of A16 (Fig. 12.2b ) . These interactions may alter the stability of the RNA pseudoknot and increase the stalled time of the ribosome on the slippery site, thus increasing the rates of −1 FS. Based on these successful results, Park applied the virtual screening strategy to discover ligands for the SARS-pseudoknot, even though its 3D structure was not completely determined. It was known that the SARS-pseudoknot has a unique 3 stem-3 loop structure. They built a 3D model using the RNA pseudoknot predicting program (PSEUDOVIEWER) and Sybyl molecular modeling software, and then Three-dimensional structural model of the SARS-pseudoknot used in this study. It was optimized by molecular dynamics simulation using the Amber 8.0 program. Brown ribbon renders the phosphate backbone of the RNA pseudoknot optimized the RNA structure by AMBER molecular dynamics simulation (Case et al. 2005 ) (Fig. 12.3 ). Using the DOCK 4.0 program, fl exible docking of a commercially-available chemical DB (Leadquest) was conducted. The chemical DB was the same as that previously used for screening against the biotin aptamer RNA pseudoknot. A total of 35 compounds inhibited −1 FS, and three structurally analogous compounds ( 43 , 21 , and 10 in Fig. 12 .4 ) reduced −1 FS selectively. Compound 43 was the most active, decreasing −1 FS ef fi ciency by 80%. In HEK 293 cells, 43 inhibited −1 FS in a concentration-dependent manner with an IC 50 value of approximately 0.45 m M (Park et al. 2011 ) . The docking model of 43 in complex with the SARS-pseudoknot is shown in Fig. 12 .5 , and reveals that 43 interacts with various residues including key residues to maintain −1 frameshifting ef fi ciency by hydrogen bonds. Compound 43 interacts with the carbonyl oxygen atom (O 2 ) of the U58 uracil base by hydrogen bond, and the nitrogen atom in the thiazole ring of 43 forms a hydrogen bond (2.8 Å) with the 2 ¢ -OH group of ribose of C62. The hydrogen bond between the thiazole moiety and the receptor pseudoknot was identi fi ed as one of the key intermolecular interactions. Riboswitches are highly organized domains within 5 ¢ -UTRs of mRNAs and undergo alternate conformational switches. Riboswitches consist of two domains, an aptamer domain that is a binding site for an effector metabolite, and an expression platform that prompts changes in gene expression. Upon metabolite binding, one of the riboswitch conformers is stabilized, and is capable of controlling expression of a (Miranda-Ríos et al. 2001 ; Mironov et al. 2002 ; Gilbert and Batey 2005 ) in bacteria (Winkler et al. 2002 ; Mandal et al. 2003 ) as well as in some plants and fungi (Sudarsan et al. 2003 ; Bocobza and Aharoni 2008 ) . Therefore, the aptamer domain is an essential element of gene regulation. Riboswitches were originally discovered as an antibiotic target (Blount and Breaker 2006 ; Lee et al. 2009 ; Kim et al. 2009 ) and also have the potential to be developed into designer riboswitches for genetics studies (Suess and Weigand 2008 ) . About 20 classes of riboswitches have been reported and a large number (probably up to 100) of new classes may await discovery. Among them, guanine riboswitches are one of the validated targets for development of new antibacterial drugs. X-ray crystal structures of more than 10 riboswitches have been determined, and thus structure-based drug design approaches can be applied to this target (Serganov 2010 ) . Daldrop et al. tried virtual screening to discover novel ligands targeting the purine riboswitch using the program DOCK3.5.54 with minor modi fi cation of the scoring function (Daldrop et al. 2011 ) . The Bacillus subtilis xpt-pbuX guanine riboswitch carrying a C74U mutation (called GRA, PDB id: 2G9C) (Gilbert et al. 2006 ) in complex with pyrimidine-2,4,6-triamine was used as a target receptor for docking. All docking and virtual screening studies were carried out using a slightly modi fi ed version of the DOCK3.5.54 program that incorporated RNA-speci fi c parameters to calculate van der Waals and electrostatic energies. This group fi rst tested whether native ligand was correctly reproduced in terms of its binding geometry after selfdocking. The RMSD between native ligand and the docking result was measured. RMSD was less than 0.34 Å, which showed that the docked model was close to native. Secondly, the accuracy of the prediction was tested by docking with known ligands and decoys. The test set consisted of eight known ligands, with binding af fi nities ranged from 0.01 to 100 m M. For all 15 decoys, no binding was detected at up to 300 m M; except for guanine that was tested up to its solubility limit. All compounds in the test set docked into the active site and the results were analyzed by sorting the docking scores. Seven out of the eight top-scoring compounds were true ligands and all eight compounds with lowest docking energy scores were decoys. They used their own in-house database, which included a commercially available 2,592 unique compounds. To evaluate the accuracy of binding prediction, all compounds in the database were docked into the active site and ordered by docking score. According to this list, the true positive rate (fraction of known compounds, ligands, and decoy) was plotted against the false positive (fraction of unassigned database compounds) to get a receiver operation characteristic (ROC) curve. Accuracy was calculated by measuring the area under curve (AUC) of a ROC curve value. The AUC value of ligands was 0.98 and that of decoy was 0.75, suggesting that known ligands were perfectly predicted by virtual screening and decoys were also enriched compared to random (AUC 0.5). From this result, fi ve compounds were selected to examine their binding af fi nity and modes. Three compounds out of fi ve were analogs of known ligands and two compounds were novel scaffolds. To determine the binding af fi nities, fl uorescence assays and isothermal titration calorimetry (ITC) were used. Four out of fi ve chosen compounds bound to GRA with af fi nities in the micromolar range. The rapidly increasing number of RNA crystal structures in the PDB, and the biological function studies on a variety of RNA structures have provided a basis for structure-based virtual screening targeting RNA. Due to several features of RNA (conformational fl exibility, high negative charge, and solvation) that differ from those of proteins, researchers have observed that the conventional protein-ligand docking programs have limitations in accurately predicting RNA-ligand interactions. In some studies, active molecules have been fortuitously obtained by proteintargeted docking programs. However, continuing progress has been made in the development of docking algorithms or scoring functions optimized for RNA receptors, which makes various RNA targets more amenable for structure-based drug design. As an example, consideration of receptor fl exibility is important not only for RNA-based receptors, but has also been a critical issue for protein receptors for a long time. Massive efforts have been made to incorporate protein fl exibility into docking process, but it exponentially in fl ates the potential search space and became impractical. Al-Hashimi's approaches to use RNA dynamic ensemble (Stelzer et al. 2011 ) can be practically applied to other RNA targets. RNA receptors are usually smaller than protein receptors in size, so the process to generate RNA ensembles is not extremely computationally expensive. Structure-or ligand-based virtual screening has identi fi ed a plethora of RNA binding ligands from in-house and commercially available chemical databases, originally designed and prepared for protein targets. Actually, some commercial chemical databases possess compounds which only satisfy "Lipinski's rule of fi ve (Lipinski et al. 1997 ) ". In comparing the activities of small molecule RNA binders identi fi ed by virtual screening, we realized that hits with nanomolar activity were very rare, and overall their activities are in the high micromolar range. These results were probably caused by limitations of currently available chemical database, not only by those of protein-friendly docking algorithms. In protein-targeted virtual screening of chemical databases, many hits with nanomolar or submicromolar activity were identi fi ed. Thus, another possible way to improve the hit rate of RNAtargeted virtual screening is to prepare an RNA-focused chemical database. Considering the physicochemical properties of RNA binders, a modi fi ed "Lipinski's rule of fi ve" needs to be applied to database fi ltering during virtual screening (Aboulela 2010 ) . Biased probability Monte Carlo conformational searches and electrostatic calculations for peptides and proteins Strategies for the design of RNA-binding small molecules Structure of HIV-1 TAR RNA in the absence of ligands reveals a novel conformation of the trinucleotide bulge A new algorithm for RNA secondary structure design Programmed ribosomal frameshifting in decoding the SARS-CoV genome Ef fi ciency of a programmed −1 ribosomal frameshift in the different subtypes of the human immunode fi ciency virus type 1 group M The Protein Data Bank and the challenge of structural genomics Riboswitches as antibacterial drug targets Switching the light on plant riboswitches The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure Mutational analysis of the RNA pseudoknot component of a coronavirus ribosomal frameshifting signal PseudoViewer3: generating planar drawings of large-scale RNA structures with pseudoknots The Amber biomolecular simulation programs An RNA pseudoknot and an optimal heptameric shift site are required for highly ef fi cient ribosomal frameshifting on a retroviral messenger RNA Structure-based discovery of ligands targeted to the RNA double helix The dynamic landscapes of RNA architecture Novel ligands for a purine riboswitch discovered by RNA-ligand docking VARNA: interactive drawing and editing of the RNA secondary structure RnaViz 2: an improved representation of RNA secondary structure Validation of automated docking programs for docking and database screening against RNA drug targets Decreasing the frameshift ef fi ciency translates into an equivalent reduction of the replication of the human immunode fi ciency virus type 1 RNA movies: visualizing RNA secondary structure spaces DOCK 4.0: search strategies for automated molecular docking of fl exible molecule databases Identi fi cation of ligands for RNA targets via structure-based virtual screening: HIV-1 TAR Predicting RNA structure by multiple template homology modeling A structure-based strategy to identify new molecular scaffolds targeting the bacterial ribosomal A-site Towards the discovery of drug-like RNA ligands? Constructing RNA dynamical ensembles by combining MD and motionally decoupled NMR RDCs: new insights into RNA dynamics and adaptive ligand recognition Molecular recognition of RNA: challenges for modelling interactions and plasticity Targeting RNA with small-molecule drugs: therapeutic promise and chemical challenges Rfam: updates to the RNA families database Ribosomal frameshifting: an emerging drug target for HIV Riboswitches: natural SELEXion Modi fi ed pyrimidines speci fi cally bind the purine riboswitch Docking to RNA via root-mean-square-deviation-driven energy minimization with fl exible ligands and fl exible targets Principles of docking: an overview of search algorithms and a guide to scoring functions A vector-based method for drawing RNA secondary structure Drugs targeting the ribosome Vienna RNA secondary structure server A semiempirical free energy force fi eld with charge-based desolvation A 1.3-Å resolution crystal structure of the HIV-1 trans-activation response region RNA stem reveals a metal ion-dependent bulge conformation Expression of the Rous sarcoma virus pol gene by ribosomal frameshifting Identi fi cation of functional, endogenous programmed −1 ribosomal frameshift signals in the genome of Saccharomyces cerevisiae Sur fl ex: fully automatic fl exible molecular docking using a molecular similaritybased search engine Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation Coarse-grained modeling of large RNA molecules with knowledge-based potentials and structural fi lters Sequence to structure (S2S): display, manipulate and interconnect RNA data from sequence to structure Assemble: an interactive graphical tool to analyze and build RNA architectures at the 2D and 3D levels A mutant RNA pseudoknot that promotes ribosomal frameshifting in mouse mammary tumor virus Calculation of ligand-nucleic acid binding free energies with the generalized-born model in DOCK Comparative evaluation of eight docking tools for docking and virtual screening accuracy Design and antimicrobial action of purine analogues that bind Guanine riboswitches Docking and scoring in virtual screening for drug discovery: methods and applications The bacterial ribosome, a promising focus for structure-based drug design Evaluation of the FLEXX incremental construction algorithm for protein-ligand docking DOCK 6: combining techniques to model RNA-small molecule complexes Roseo fl avin is a natural antibacterial compound that binds to FMN riboswitches and regulates gene expression Accuracy assessment of protein-based docking programs against RNA targets Structure-based computational database screening, in vitro assay, and NMR assessment of compounds that target TAR RNA Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Riboswitches control fundamental biochemical pathways in Bacillus subtilis and other bacteria 3D database searching in drug design RNA2D3D: a program for generating, viewing, and comparing 3-dimensional models of RNA RNAdraw: an integrated program for RNA secondary structure calculation and analysis under 32-bit Microsoft Windows Virtual screening strategies in drug discovery A conserved RNA structure (thi box) is involved in regulation of thiamin biosynthetic gene expression in bacteria Sensing small molecules by nascent RNA: a mechanism to control transcription in bacteria Docking of aminoglycosides to hydrated and fl exible RNA Validation of an empirical RNA-ligand scoring function for fast fl exible docking using Ribodock Automated docking using a lamarckian genetic algorithm and an empirical binding free energy function The crisis in antibiotic resistance The 1.3 Å crystal structure of a biotin-binding pseudoknot and the basis for RNA molecular recognition The MC-fold and MC-Sym pipeline infers RNA structure from sequence data Identi fi cation of novel ligands for the RNA pseudoknot that regulate −1 ribosomal frameshifting Identi fi cation of RNA pseudoknot-binding ligand that inhibits the −1 ribosomal frameshifting of SARS-Coronavirus by structure-based virtual screening Competitive inhibition of human immunode fi ciency virus type-1 protease by the Gag-Pol transframe protein HIV treatment failure: testing for HIV resistance in clinical practice Discovery of ligands for a novel target, the human telomerase RNA, based on fl exible-target virtual screening and NMR A three-stemmed mRNA pseudoknot in the SARS coronavirus frameshift signal Conformation of the TAR RNA-arginine complex by NMR spectroscopy New inhibitors of the tat-tar RNA interaction found with a "Fuzzy ModeRNA: a tool for comparative modeling of RNA 3D structure Essential factors for successful virtual screening Determination of riboswitch structures: light at the end of the tunnel? iFoldRNA: three-dimensional RNA structure prediction and folding Modi fi cations of the scoring function in FlexX for virtual screening applications Discovery of selective bioactive small molecules by targeting an RNA dynamic ensemble An atypical RNA pseudoknot stimulator and an upstream attenuation signal for −1 ribosomal frameshifting of SARS coronavirus Metabolite-binding RNA domains are present in the genes of eukaryotes Engineered riboswitches: overview, problems and trends YUP: a molecular simulation program for coarse-grained and multiscaled models Identi fi cation and analysis of the pseudoknot-containing gag-pro ribosomal frameshift signal of simian retrovirus-1 Ribosomal frameshifting requires a pseudoknot in the Saccharomyces cerevisiae double-stranded RNA virus Structure-based virtual ligand screening: recent success stories Thiamine derivatives bind messenger RNAs directly to regulate bacterial gene expression Discoveries of Tat-TAR interaction inhibitors for HIV-1 Tools for the automatic identi fi cation and classi fi cation of RNA base pairs Visualizing spatially correlated dynamics that directs RNA conformational transitions New linear interaction method for binding af fi nity calculations using a continuum solvent model Three-dimensional comparative modeling of RNA